Fluzoparib

Generic Name: Fluzoparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₆F_₄N_₆O_₂

CAS Number: 1358715-18-0

Unique Ingredient Identifier: TWF0ML1CK8

Background: Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

Indication: ⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

First Posted Date: 2022-10-17

Last Posted Date: 2024-08-06

Lead Sponsor: Fudan University

Target Recruit Count: 716

Registration Number: NCT05582499

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Phase 2

Active, not recruiting

Conditions: High-risk Prostate Cancer
Neoadjuvant Therapy

Interventions: Drug: Abiraterone acetate
Drug: Fluzoparib
Drug: Prednisone
Drug: Androgen deprivation therapy
Procedure: Radical Prostatectomy

First Posted Date: 2022-02-04

Last Posted Date: 2023-12-08

Lead Sponsor: Fudan University

Target Recruit Count: 34

Registration Number: NCT05223582

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer

Interventions: Drug: Bevacizumab
Drug: Fluzoparib
Drug: chemotherapy

First Posted Date: 2021-12-28

Last Posted Date: 2021-12-28

Lead Sponsor: The Second Affiliated Hospital of Shandong First Medical University

Target Recruit Count: 60

Registration Number: NCT05170594

Locations: 🇨🇳
The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Fluzoparib

First Posted Date: 2021-09-02

Last Posted Date: 2024-01-19

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05032235

Locations: 🇨🇳
The second affiliated hospital of Chongqing medical university, Chongqing, Chongqing, China

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2

Conditions: Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: Fluzoparib
Drug: Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets
Drug: Fluzoparib Combined With Apatinib

First Posted Date: 2021-05-03

Last Posted Date: 2022-09-26

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 93

Registration Number: NCT04869488

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2021-04-02

Last Posted Date: 2021-05-11

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 65

Registration Number: NCT04828395

Locations: 🇨🇳
Liu ningbo, Tianjin, China

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Phase 1

Completed

Conditions: Recurrent Ovarian Cancer

Interventions: Drug: fluzoparib

First Posted Date: 2021-01-22

Last Posted Date: 2023-08-14

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 33

Registration Number: NCT04718740

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Subjects

Interventions: Drug: Fluzoparib

First Posted Date: 2021-01-05

Last Posted Date: 2024-07-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04694365

Locations: 🇨🇳
Henan Infectious Diseases Hospital, Zhengzhou, Henan, China

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Phase 1

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Drug: Fluzoparib
Drug: Apatinib

First Posted Date: 2020-12-09

Last Posted Date: 2020-12-09

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 53

Registration Number: NCT04659785

Locations: 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China

Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Fluzoparib

First Posted Date: 2020-09-02

Last Posted Date: 2023-06-13

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 1

Registration Number: NCT04535687

Locations: 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy